DelfaGLP-1 Atlas

Lead sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

11 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

11

Trials led

1

Active

3,329

Total enrollment

6

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
3
Phase 2
4
Phase 3
4

Trials by status

Recruiting
1
Completed
7
Unknown
3

Trials led

A Study of TG103 Injection in Non-diabetic Overweight or ObesityBMI ≥28Ph 3Completed675
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusBMI ≤40Ph 3Completed632
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes MellitusBMI ≤40Ph 3Completed465
Semaglutide in Treatment of ObesityBMI ≥28Ph 3Completed462
A Study of TG103 Injection in the Management of Non-diabetic Overweight or ObesityBMI ≥28Ph 2Completed314
A Study of TG103 Injection in Type 2 Diabetes SubjectsBMI ≤40Ph 2Unknown240
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 DiabetesBMI ≥24Ph 2Unknown208
A Study of TG103 Injection in Overweight or ObesityBMI ≥28Ph 2Unknown195
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and ObesityBMI 24-28Ph 1Recruiting66
A Study of TG103 Injection in Overweight/Obese Subjects Without DiabetesBMI ≥26Ph 1Completed48
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male SubjectsBMI 19-26Ph 1Completed24